Endocan Corp Stock Net Asset
| ENDO Stock | USD 0.0001 0.00 0.00% |
Endocan Corp fundamentals help investors to digest information that contributes to Endocan Corp's financial success or failures. It also enables traders to predict the movement of Endocan Pink Sheet. The fundamental analysis module provides a way to measure Endocan Corp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Endocan Corp pink sheet.
Endocan |
Endocan Corp Company Net Asset Analysis
Endocan Corp's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Endocan Corp Net Asset | 359 |
Most of Endocan Corp's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Endocan Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Endocan Corp has a Net Asset of 359. This is much higher than that of the Basic Materials sector and significantly higher than that of the Specialty Chemicals industry. The net asset for all United States stocks is notably lower than that of the firm.
Endocan Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Endocan Corp's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Endocan Corp could also be used in its relative valuation, which is a method of valuing Endocan Corp by comparing valuation metrics of similar companies.Endocan Corp is currently under evaluation in net asset category among its peers.
Endocan Fundamentals
| Current Valuation | 1.87 M | |||
| Shares Outstanding | 67.89 M | |||
| Price To Earning | (0.09) X | |||
| Price To Book | 18.51 X | |||
| Net Income | (3.31 M) | |||
| Cash And Equivalents | 59 | |||
| Total Debt | 954.59 K | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (105.94 K) | |||
| Earnings Per Share | (0.12) X | |||
| Number Of Employees | 31 | |||
| Beta | 2.53 | |||
| Market Capitalization | 1.6 M | |||
| Total Asset | 359 | |||
| Retained Earnings | (32.94 M) | |||
| Working Capital | (1.49 M) | |||
| Current Liabilities | 1.49 M | |||
| Net Asset | 359 |
About Endocan Corp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Endocan Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Endocan Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Endocan Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Endocan Pink Sheet
Endocan Corp financial ratios help investors to determine whether Endocan Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Endocan with respect to the benefits of owning Endocan Corp security.